These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9867152)

  • 1. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
    van Rensburg AJ; Alberts AS; Louw WK
    J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
    Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
    Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
    Cameron PJ; Klemp PF; Martindale AA; Turner JH
    Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE; Macey DJ; Kasi LP; Fossella FV
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
    Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
    J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Samarium for osteoblastic bone metastases and osteosarcoma.
    Anderson P
    Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESR dosimetry of 89Sr and 153Sm in bone.
    Kinoshita A; Braga FJ; Graeff CF; Baffa O
    Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
    Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of BMI in dosimetry of
    Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
    Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study on the feasibility of real-time calculation of three-dimensional dose distribution for (153)Sm-EDTMP radionuclide therapy based on the voxel S-values.
    Feng G; Lixin C; Xiaowei L; Tsao SY; Weiguang Z; Wei F
    Cancer Biother Radiopharm; 2010 Jun; 25(3):345-52. PubMed ID: 20578840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
    Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
    Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
    [No Abstract]   [Full Text] [Related]  

  • 17. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J; Vizd'a J; Cermáková E
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
    Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
    Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
    Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
    J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
    Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
    J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.